• About Us
    • Contact Us
    • Login
    • ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
About Us Contact Us Login ObGFirst
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • COVID-19
The Genome
CMECNE

Consensus Guideline: Treatment Options for Hereditary Breast Cancer

image_pdfFavoriteLoadingFavorite

Learning Objectives and CME/Disclosure Information

This activity is intended for healthcare providers delivering care to women and their families.

After completing this activity, the participant should be better able to:

1. Discuss the recommended surgical treatment for hereditary breast cancer
2. Describe the recommended medical treatment for hereditary breast cancer

Estimated time to complete activity: .25 hours

Faculty:

Susan J. Gross, MD, FRCSC, FACOG, FACMG President and CEO, The ObG Project

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.


The PIM planners and others have nothing to disclose. The OBG Project planners and others have nothing to disclose.

Faculty: Susan J. Gross, MD, receives consulting fees from Cradle Genomics, and has financial interest in The ObG Project, Inc.

Planners and Managers: The PIM planners and managers, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, MBA, MSN, RN, and Jan Schultz, MSN, RN, CHCP have nothing to disclose.

Method of Participation and Request for Credit

Fees for participating and receiving CME credit for this activity are as posted on The ObG Project website. During the period from 12/01/2022 through 12/01/2024, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgment for completing this activity, please complete the test and evaluation. Upon registering and successfully completing the test with a score of 100% and the activity evaluation, your certificate will be made available immediately.

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and The ObG Project. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Postgraduate Institute for Medicine designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education

The maximum number of hours awarded for this Continuing Nursing Education activity is .25 contact hours.

Read Disclaimer & Fine Print

SUMMARY: 

American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO), and Society of Surgical Oncology (SSO) have published a guideline for management of individuals with hereditary breast cancer. The guideline was developed to standardize care among individuals carrying a pathogenic mutation, with a focus on BRCA1/2, PALB2, CHEK2, TP53 and ATM germline mutations. The guideline was created by a consensus panel of 52 members, and funded by ASCO.

Background

  • The majority of breast cancer is sporadic (no family history)
  • 15 to 20% of breast cancer is familial (clustering with significant family history, but no pathogenic mutation identified)
  • 5 to 10% of breast cancer is hereditary and associated with a germline mutation
  • High penetrance genes such as BRCA1/2 confer a lifetime breast cancer risk of 70%
  • Moderate penetrance genes confer a lower risk
    • PALB2: 35 to 60%
    • ATM and CHEK2: 25 to 30% mutations

Key Recommendations

Surgical treatment

  • Patients with newly diagnosed hereditary breast cancer can be offered breast-conserving therapy (BCT)
  • Patients who are BRCA1/2 carriers are at increased risk of contralateral breast cancer (CBC)
  • Discuss the option of bilateral mastectomy (with contralateral risk-reducing mastectomy (CRRM))
    • Consideration of family history, age at diagnosis, comorbidities, life expectancy and ability for the patient to undergo breast surveillance should be a part of this conversation
  • Patients who do not have bilateral mastectomy
    • Offer high-risk screening of the remaining breast tissue with annual mammogram and magnetic resonance imaging
  • For patients who request CRRM
    • Nipple-sparing mastectomy (NSM) is a reasonable approach
    • There is limited evidence for CRRM in patients with moderate-penetrance genes (PALB2, ATM, and CHEK2) | Additional factors can be considered such as age at diagnosis and family history
  • TP53 mutation carriers
    • Offer mastectomy because radiation therapy is contraindicated unless the risk of locoregional recurrence is high 

Medical Treatment

  • Advanced BRCA-associated breast cancer
    • Platinum agents are recommended versus taxanes
    • There are no data to address platinum efficacy in other germline mutations
  • Poly ADP-ribose polymerase (PARP) inhibitors
    • Recommended for metastatic HER2-negative BRCA-associated breast cancer as an alternative to chemotherapy for first- to third-line therapy
    • No evidence exists to support the use of PARP inhibitor in patients with moderate penetrance genes

Note: A recent publication in the NEJM supports the role for adjuvant olaparib, a PARP inhibitor, for the treatment of HER2-negative early breast cancer specifically for patients with germline BRCA1 or BRCA2 pathogenic or likely pathogenic variants

Learn More – Primary Sources

Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline

Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer

Take a post-test and get CME credits

TAKE THE POST TEST

Want to stay on top of key guidelines and research papers?

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All The Genome Posts
Next >

Related ObG Topics:

USPSTF Guidelines for Primary Care Clinicians: BRCA-Related Cancer Risk Assessment
Prophylactic Mastectomy and BRCA – Risk Reduction and Guidelines
BRCA1 & BRCA2 Mutations: What Are the Risks for Developing Breast and Ovarian Cancer?
Is Pregnancy After Breast Cancer Safe for Women with BRCA Mutations?
ACMG Statement on Genetic Testing for All Breast Cancer Patients

Sections

  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • COVID-19

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site